Clinician's Guide to Spinal Muscular Atrophy

Jump to:
Medical advisors icon

Meet our

Medical advisors

Edward Smith, M.D.

Edward Smith, MD

Melissa Wright, MD, PhD

Spinal Muscular Atrophy: A Clinical Overview

Written by Margaret Anne Rockwood | Last updated July 3rd, 2026
✅ Medically reviewed by Edward Smith, MD

 

Spinal muscular atrophy (SMA) is a familial neuromuscular disease marked by progressive degeneration of lower motor neurons, leading to muscle weakness, hypotonia and – in severe cases – respiratory and feeding failure.

Most cases of SMA are caused by a defective survival motor neuron 1 (SMN1) gene; this gene is responsible for making proteins critical to motor neuron survival. Its heritability is often undetectable, since each parent with the genetic variant typically has one functional SMN1 gene copy that makes enough SMN protein to prevent symptoms.

Carrier frequency is relatively high for this rare disorder because SMA is autosomal recessive. Reported carrier frequency in the general population is often about 1 in 40 to 1 in 60, with some European ancestry estimates around 1 in 45. Carrier detection can be complicated by “silent carriers,” who have two SMN1 copies on one chromosome and none on the other, making some standard dosage tests appear normal.

Approximately 1 in 50 people globally carry one copy of the variant; if two carriers have a child, there is a 25% chance the child will have SMA, a 50% chance the child will be a carrier, and a 25% chance the child will be unaffected/non-carrier.

Globally, an estimated 100,000 -200,000 people live with SMA.

SMA Types

Types of SMA have traditionally been distinguished based on age at onset and the number of motor milestones achieved.

Type 0 (<1% of cases) begins prenatally and is the most severe. These newborns have decreased movement in the womb and are profoundly weak at delivery. They tend to survive only a short time without intensive respiratory support. New treatments may lengthen survival slightly, but neuronal damage in utero is typically determinative of poor survival after birth.

Type 1, also known as Werdnig-Hoffmann disease (~50 to 60% of cases), presents before 6 months of age. Untreated infants never learn to sit independently and often die of respiratory failure by age 2. With new therapies, however, research has shown that many children treated within a critical window live 5 to 10-plus years.

Type 2 (~20-30% of cases) usually begins between 6 and 18 months. Children can sit but do not walk independently, and many lose their sitting ability over time. Survival has traditionally been into adulthood or middle age with good respiratory and orthopaedic care. Clinicians and families can expect extended survival when new therapies are provided early enough in life.

Type 3, also known as Kugelberg-Welander disease (~10 to 20% of cases), begins after 18 months. Patients achieve walking but may lose ambulation later. Survival into middle and older age is common.

Type 4 (<5% of cases) begins in adulthood and is usually milder. Patients may have a normal life expectancy.

This classification remains useful, but the phenotype is evolving as a result off newborn screening and disease-modifying therapy (DMTs). Three major treatments have altered the natural history:

  • nusinersen, an intrathecal antisense oligonucleotide that modifies SMN2 RNA splicing
  • onasemnogene abeparvovec-xioi, a gene-replacement therapy
  • zonasemnogene-abeparvovec-xioi, also a gene -replacement therapy
  • risdiplam, an oral SMN2 splicing modifier

Newborn Screening & Carrier Testing

Optimal treatment of SMA begins pre-symptomatically, before significant irreversible motor-neuron loss has occurred. Newborn screening has therefore become central to modern SMA care.

Even though SMA is rare, it is one of the most important genetic causes of infant morbidity and mortality. A widely cited systematic review estimated overall SMA prevalence at about 1 to 2 per 100,000 persons and incidence at roughly 1 in 10,000 live births, while other reviews place birth incidence around 1 in 10,000 to 20,000 live births, reflecting differences in ascertainment, ethnicity, diagnostic era and screening methods.

With earlier diagnosis, ventilatory support, and disease-modifying therapies, survival is dramatically improving, so prevalence is expected to rise over time even if birth incidence remains stable.

Screening programs can help to detect homozygous SMN1 exon 7 deletion, the most common genetic mechanism in SMA. However, it’s important to recognize that screeners may miss rare compound heterozygotes with one deletion and one point mutation.

Screening may also raise counseling issues for families of infants with higher SMN2 copy numbers who may have later-onset or milder disease, making caregiver education crucial.

Sources